Meeting
2018 ASCO Annual Meeting
The BRIGHTER trial: A phase 3 randomized double-blind study of napabucasin (NAPA) plus paclitaxel (PTX) versus placebo (PBO) plus PTX in patients (pts) with pretreated advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma.
Authors
Manish A. Shah
Weill Cornell Medicine/ New York Presbyterian Hospital, New York, NY
Manish A. Shah , Kohei Shitara , Florian Lordick , Yung-Jue Bang , Niall C. Tebbutt , Jean-Philippe Metges , Kei Muro , Lin Shen , Sergei Tjulandin , John L. Hays , Rui-hua Xu , Marilyn Fontaine , Emily Brooks , Bo Xu , Wei Li , Chiang Li , Laura Borodyansky , Eric Van Cutsem
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Esophageal or Gastric Cancer
Clinical Trial Registration Number
NCT02178956
Citation
J Clin Oncol 36, 2018 (suppl; abstr 4010)
DOI
10.1200/JCO.2018.36.15_suppl.4010
Abstract #
4010
Poster Bd #
199
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
The BRIGHTER trial: A phase III randomized double-blind study of BBI-608 + weekly paclitaxel versus placebo (PBO) + weekly paclitaxel in patients (pts) with pretreated advanced gastric and gastro-esophageal junction (GEJ) adenocarcinoma.
First Author: Manish A. Shah
Poster
2015 ASCO Annual Meeting
The BRIGHTER trial: A phase III randomized double-blind study of BBI608 + weekly paclitaxel versus placebo (PBO) + weekly paclitaxel in patients (pts) with pretreated advanced gastric and gastro-esophageal junction (GEJ) adenocarcinoma.
First Author: Manish A. Shah
Poster
2015 Gastrointestinal Cancers Symposium
RAINBOW: A global, phase 3, double-blind study of ramucirumab (RAM) plus paclitaxel (PTX) versus placebo (PL) plus PTX in the treatment of advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma following disease progression on first-line platinum- and fluoropyrimidine-containing combination therapy—An age-group analysis.
First Author: Kei Muro
Poster
2014 ASCO Annual Meeting
RAINBOW: A global, phase III, randomized, double-blind study of ramucirumab plus paclitaxel versus placebo plus paclitaxel patients with previously treated gastric or gastroesophageal junction (GEJ) adenocarcinoma: Quality-of-life (QoL) results.
First Author: Salah-Eddin Al-Batran